Beta-O2 is developing the ßAir Bio-artificial Pancreas, intended to cure Type 1 diabetes (TID). Patients with TID are unable to produce insulin, a hormone needed to transport sugar into cells, providing the energy needed for daily life. ßAir provides a viable and safe environment for islets of Langerhans (insulin producing beta cells), to thrive and provide the body with insulin on demand. It is able to do so, as Beta-O2 has solved the major challenges of islet transplantation – creating a protective environment where the cells can thrive but where the patient doesn’t need to take life-long immunosuppression drugs with unpleasant side effects, and of crucial importance, keeping the cells alive and functioning inside the recipient’s body.
Looking for a particular Beta-o2 Technologies Ltd. employee's phone or email?
The Beta-o2 Technologies Ltd. annual revenue was $6.2 million in 2026.
Konstantin Bloch is the Scientific co-founder of Beta-o2 Technologies Ltd..
5 people are employed at Beta-o2 Technologies Ltd..
The NAICS codes for Beta-o2 Technologies Ltd. are [325, 32, 3254, 32541].
The SIC codes for Beta-o2 Technologies Ltd. are [283, 28].